A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)

NCT07108816 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

52

Enrollment

OTHER_GOV

Sponsor class

Conditions

Resectable Stage II-IIIB NSCLC

Interventions

DRUG: Neoadjuvant Sacituzumab tirumotecan + tagitanlimab Followed by adjuvant tagitanlimab

Sponsor

Henan Cancer Hospital